|--|--|

Approved for use through 10/31/2002. OMB 0651-0000 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the paper of t Attorney Docket No. PF526

	Į įv		UIILIIY		F	irst Invento	or	Ruben et al.	ה		
	<u></u>	PATENT APPLICATION			7	itle	HUMAN TU	MOR NECR	OSIS FACTOR		
	E ∽		TRANSMITTAL				TR18 AND N	METHODS B	SASED THEREON		
	י פי	(Only for new	nonprovisional applications under 3	CFR ' 1.53(b))	E	xpress Mai	il Label No.				
	9		PPLICATION ELEMENT poter 600 concerning utility patent app		ΑĽ	DRESS	TO. Box	nunissioner for Paten Patent Application shington, DC 20231	its		
	1. 🛛		mittal Form (e.g., PTO/SB/17)		7. [ge table or Computer					
	2. 🔲		claims small entity status.		Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)						
		See 37 CFR 1.27.					omputer Readable				
	3. 🛛	Specifica		<u>287</u>]	1	b. ⊠Spec ;	cification Sequence	e Listing on: · CD-R (2 copies)	· or		
		- Descriptive	rangement set forth below) title of the Invention		i. ii.	paper	CD-K (2 copies)	, 01			
<u>.</u>		- Statement R	ence to Related Applications Regarding Fed sponsored R & D	Related Applications				g identity of above	e copies		
U m		- Reference to sequence listing, a table, or a computer program listing appendix				C. 🛛 St	COMPANYIN	G APPLICAT	ION PARTS		
#1 #1		- Brief Summ	l of the Invention ary of the Invention iption of the Drawings (if filed)		9.		gnment Papers				
		 Detailed De Claim(s) 	escription		10	_		<u></u>	Power of Attorney		
	 		the Disclosure	. ,	10.	_	CFR 3.73(b) Sta				
ļ±	4.		[Tot	s,, _) al Sheets _] al Dance 21	11.	☐ Engl	lish Translation	Document (if app	plicable)		
5	5. 🛛	Oath of D	eclaration (unexecuted) [Tot	12.	☐ Info	rmation Disclos	sure Statement/	re Statement/ Form PTO/SB/08			
			executed (original or copy) from a prior application (37)	CFR 1.63(d))	Copies of Citations						
H- H.H T.H R.A H.H		□	ntinuation/divisional with Box 17		13. Preliminary Amendment						
	i	DELE1	ΓΙΟΝ OF INVENTOR(S)		14. Return Receipt Postcard (MPEP 503)						
14	,		tatement attached deleting invent application, see 37 CFR + 1.63		(should be specifically itemized)						
					15. Certified copy of Priority Document(s)						
	^{6.} 🛛	Application	Data Sheet. See 37 CFR 1.	76.	(if foreign priority is claimed)						
					16. Request and Certification Under 35 U.S.C. §122(b)(2)(B)(i)						
		17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:									
	[Pr	Continuation	n Divisional En information: Examiner	Continuation-in-Part	(CII	') of p	prior application N Group/Art Unit:		· 		
	For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.										
	18. CC	18. CORRESPONDENCE ADDRESS									
		Customer [Number or Bar Code Lab	el 📗	2195	or [Corresponden	ce address below			
	NAME	•							· <u> </u>		
	ADDRE	SS		STATE				710 CODE			
	COUNT	rnv		STATE				FAX	 		
	COUNT		 	TELEPHONE		В :	At BY		02		
		(Print/Type)	Kenley K. Hoover			Kegistr	ation No. (Attorney				
	SIGNA	TIIRF						1 Date	May 4, 2001		



PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

j c	FF
2 5	
E :	İ

amount of payment

EE TRANSMITTAL - ... for FY 2001

Patent fees are subject to annual revision.

\$1322.00

Complete if Known				
Application Number	To be assigned			
Filing Date	May 4, 2004			
First Named Inventor	RUBEN et al.			
Examiner Name	To be assigned			
Art Unit	To be assigned			
Attorney Docket Number	PF526			

METHOD OF PAYMENT					FEE CALCULATION (continued)							
1. The Commissioner is hereby authorized to charge					3.	ADDITI	ONAL	FEES				
indicated fees and credit any overpayments to:								Large		Small		
Deposit Account Number 08-3425							Fee	Entity	Fee	Entity Fee		
Deposit Account Name Human Genome Sciences, Inc.						es, Inc.	Code	Fee (\$)	Code	(S)	Fee Description	Fee Paid
Charge Any Additional Fee Required							105	130	205	65	Surcharge - late filing fee or oath	
_ U	nder 37	CFR §§ 1.	16 and 1.	17			127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
		t claims sm FR 1.27	an entity	status.			139	130	139	130	Non-English specification	
	 3. C						147	2,520	147	2,520	For filing a request for ex parte reexamination	
2. Payment Enclosed:					112	920°	112	920*	Requesting publication of SIR prior to Examiner action			
	☐ Check ☐ Credit Card ☐ Money Order ☐ Other*					113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
7		FEE	CALC	CULATIO	ON		115	110	215	55	Extension for reply within first month	
]1. BASI	C FILI	NG FEE					116	390	216	195	Extension for reply within second month	
Large I	Entity	Small	Entity				117	890	217	445	Extension for reply within third month	
≃ Code	Fee (\$)	Fee Code	Fee (\$)	Fee De	scription	Fee Paid	118	1,390	218	695	Extension for reply within fourth month	
101	710	201	355	Utility fili	ing fee	710.00	128	1,890	228	945	Extension for reply within fifth month	
106	320	206	160	Design fil	ling fee		119	310	219	155	Notice of Appeal	L
107	490	207	245	Plant filin	-		120	310	220	155	Filing a brief in support of an appeal	
108	710	208	355	Reissue fi	iling fee		121	270	122	135	Request for oral hearing	
114	150	214	75	Provision	al filing fee	·	138	1,510	138	1,510	Petition to institute a public use proceeding	
			SURTO	OTAL (1)		\$710.00	140	110	240	55	Petition to revive -unavoidable	
Ŭ.			SODIC	JIAL (I)		\$/10.00	141	1,240	241	620	Petition to revive - unintentional	
2. EXTR	A CLA	IM FEES					142	1,240	242	620	Utility issue fee (or reissue)	
. H	_		_	Extra Claims	Fee from below	Fee Paid	143	440	243	220	Design issue fee	
Total Cla	-	39	-20	19	\$18.00	342.00	144	600	244	300	Plant issue fee	
≓ Independ ≟ Claims	Jent	3	-3*	0	\$80.00	0.00	122	130	122	130	Petitions to the Commissioner	
Multiple	Depen	dent			\$270.00	270.00	123	50	123	50	Petitions related to provisional applications	ļ
[•			ļ			126	180	126	180	Submission of Information Disclosure Statement	ļ
Large E		Small E					581	40	481	40	Recording each patent assignment per property (times number of properties)	
Fee Code	Fee (\$)	Fee Code	Fee (\$)				146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
103	18	203	9	Claims in excess of 20			149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
102	80	202	40	Independent claims in excess of 3		179	710	279	355	Request for Continued Examination (RCE)		
104	270	204	135	Multiple dependent claim, if not paid		169	900	169	900	Request for expedited examination of a design application		
108	80	209	40	Reissue independent claims over original patent			Other f	ee (specify)) :			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent					Other f	ee (specify)) :					
		S	UBTO	TAL (2)		\$612.00	Other f	ee (specify)) :			
·· or	or number previously paid, if greater; For Reissues, see above				Redu	ced by Basi	c Filing F	ee Paid	SUBTOTAL (3)	\$0.00		

Submitted By	•	Complete (if applicable)
Name (Print/Type) Kenley K. Hoover	Registration No.: 40,302	Telephone 301-309-8504
Signature: M. Hru		Date: May 4, 2001



	Filing Date	May 4, 2001
REQUEST AND	First Named Inventor	Ruben et al.
CERTIFICATION	Title	HUMAN TUMOR NECROSIS FACTOR TR18 AND METHODS
33 0.0.0. 122(b)(2)(b)(1)	Attny.	BASED THEREON PF526
	Docket Number	·

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

Kenley K. Hoover Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application upon filing.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.